|
WO2021080983A1
|
|
Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
|
|
WO2021067820A1
|
|
Formulation of antibody-drug conjugate
|
|
WO2021067861A1
|
|
Camptothecin peptide conjugates
|
|
WO2021067776A2
|
|
Anti-pd-l1 antibodies and antibody-drug conjugates
|
|
WO2021062122A1
|
|
Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
|
|
WO2021055865A1
|
|
Selective drug release from internalized conjugates of biologically active compounds
|
|
WO2021046139A1
|
|
Double-digestion assay for analyzing ligand-drug conjugates
|
|
US2021030885A1
|
|
Humanized anti-liv1 antibodies for the treatment of cancer
|
|
SG11202101429YA
|
|
Anti-tigit antibodies
|
|
AU2018375412A1
|
|
Process for the preparation of drug linker compounds
|
|
AU2018359546A1
|
|
Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
|
|
AU2018258663A1
|
|
Treatment of HER2 positive cancers
|
|
AU2016287647A1
|
|
Anti-NTB-A antibodies and related compositions and methods
|
|
AU2013364043A1
|
|
Anti-NTB-A antibodies and related compositions and methods
|
|
AU2012211500A1
|
|
Humanized anti-CD70 binding agents and uses thereof
|
|
AU2012200923A1
|
|
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
|
AU2011316917A1
|
|
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
|
|
AU2007200173A1
|
|
Recombinant anti-CD30 antibodies and uses thereof
|
|
AU2006269422A1
|
|
Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
|
|
AU2004213053A1
|
|
Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
